Quarterly report [Sections 13 or 15(d)]

Subsequent Events (Details Narrative)

v3.25.3
Subsequent Events (Details Narrative) - USD ($)
 3 Months Ended
Dec. 02, 2025
Oct. 22, 2025
Sep. 30, 2025
Dec. 08, 2025
Subsequent Event [Line Items]        
Common stock, par or stated value per share     $ 0.01  
Stock issued during period, value, new issues     $ 0  
Common stock, shares, outstanding     100  
Common stock, shares authorized     1,000  
Common Stock [Member]        
Subsequent Event [Line Items]        
Stock issued during period, shares, new issues     100  
Stock issued during period, value, new issues     $ 0  
Subsequent Event [Member] | Series A Preferred Stock [Member]        
Subsequent Event [Line Items]        
Preferred stock, par or stated value per share $ 1,000      
Preferred stock, shares issued 200,000      
Preferred stock, convertible, conversion price $ 6.25      
Percentage of beneficially owner in excess of preferred stock 4.99%      
Percentage of beneficially owner of preferred stock holder 9.99%      
Subsequent Event [Member] | Common Stock [Member]        
Subsequent Event [Line Items]        
Common stock, shares authorized 2,000,000,000      
Share Repurchase Program, Authorized, Amount       $ 30,000,000
Subsequent Event [Member] | Preferred Stock [Member]        
Subsequent Event [Line Items]        
Preferred stock, shares authorized 100,000,000      
Preferred stock, par or stated value per share $ 0.01      
Subsequent Event [Member] | LifeSci Capital LLC [Member]        
Subsequent Event [Line Items]        
Payments to acquire businesses, gross   $ 50,000    
Subsequent Event [Member] | Equity Incentive Plan 2025 [Member]        
Subsequent Event [Line Items]        
Common stock, capital shares reserved for future issuance 6,351,278      
Subsequent Event [Member] | Advisor Rights Agreement [Member]        
Subsequent Event [Line Items]        
Class of warrant or right, number of securities called by each warrant or right 9,131,600      
Subsequent Event [Member] | Advisor Rights Agreement [Member] | First Advisor Warrant [Member]        
Subsequent Event [Line Items]        
Class of warrant or right, exercise price of warrants or rights $ 9.375      
Subsequent Event [Member] | Advisor Rights Agreement [Member] | Second Advisor Warrant [Member]        
Subsequent Event [Line Items]        
Class of warrant or right, exercise price of warrants or rights 12.5      
Subsequent Event [Member] | Advisor Rights Agreement [Member] | Third Advisor Warrant [Member]        
Subsequent Event [Line Items]        
Class of warrant or right, exercise price of warrants or rights 18.75      
Subsequent Event [Member] | Contingent Value Rights Agreement [Member]        
Subsequent Event [Line Items]        
Common stock, par or stated value per share $ 0.0001      
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member]        
Subsequent Event [Line Items]        
Business combination, effective date of acquisition Dec. 02, 2025      
Common stock, shares, outstanding 127,025,563      
Class of warrant or right, number of securities called by warrants or rights 2,809,001      
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Series A Preferred Stock [Member]        
Subsequent Event [Line Items]        
Preferred stock, shares outstanding 166,172.794      
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]        
Subsequent Event [Line Items]        
Conversion of stock, shares converted 26,587,647      
Subsequent Event [Member] | Sonnet BioTherapeutics Holdings, Inc. [Member] | Advisor Warrants [Member]        
Subsequent Event [Line Items]        
Class of warrant or right, number of securities called by warrants or rights 27,394,800      
Subsequent Event [Member] | Rorschach Advisors LLC [Member]        
Subsequent Event [Line Items]        
Number of cryptocurrency token 12,500,000      
Subsequent Event [Member] | Rorschach Advisors LLC [Member] | Common Stock [Member]        
Subsequent Event [Line Items]        
Common stock, par or stated value per share $ 1.25      
Stock issued during period, shares, new issues 7,761,860      
Stock issued during period, value, new issues $ 299,900,000      
Subsequent Event [Member] | Rorschach Advisors LLC [Member] | Advisor Rights Agreement [Member]        
Subsequent Event [Line Items]        
Business combination, voting equity interest acquired, percentage 10.00%      
Sale of stock, percentage of ownership after transaction 150.00%      
Percentage of common share issue 5.00%      
Percentage of number of share warrant for common share issue 15.00%      
Subsequent Event [Member] | Chardan Capital Markets LLC [Member]        
Subsequent Event [Line Items]        
Business combination, description of acquiree   The Company was required to pay a $25,000 fee upon execution of the Facility and paid $125,000 on the Closing Date. Additional commitment fees will be required depending on the amount of shares sold by the Company including $250,000 payable once the Company has received an aggregate of $25,000,000 in proceeds from sales of Common Stock under the Purchase Agreement and $625,000 payable once the Company has received an aggregate of $50,000,000 in proceeds from sales of Common Stock under the Purchase Agreement.    
Subsequent Event [Member] | Chardan Capital Markets LLC [Member] | Common Stock [Member]        
Subsequent Event [Line Items]        
Stock purchased during period shares   160,000,000    
Stock purchased during period value   $ 1,000,000,000